Exelixis, Inc. 10-Q Summary: Quarter Ended April 1, 2011
Business Context and Reporting Period
Exelixis, Inc. is a biotechnology company focused on developing small molecule therapies for cancer. The company has shifted its strategy to focus exclusively on the development and commercialization of its most advanced compound, cabozantinib (XL184), while out-licensing other programs to partners. This report covers the quarterly period ended April 1, 2011 (referred to as March 31, 2011, for convenience).
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $35.9 million | $42.2 million |
| Net Loss | $(27.5) million | $(43.2) million |
| Loss Per Share (Basic & Diluted) | $(0.24) | $(0.40) |
| Cash and Cash Equivalents | $202.1 million | $58.3 million |
| Total Investments (Marketable + Long-term) | $185.4 million | $152.5 million |
| Total Debt (Current + Long-term) | $208.0 million | $208.5 million |
| Working Capital | $126.1 million | $(16.5) million |
Note: Working capital calculated as Total Current Assets minus Total Current Liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by 14.9% ($6.3 million) compared to Q1 2010. This was primarily due to the absence of a one-time $7.0 million milestone payment from Genentech in 2010 and a reduction in license revenue recognition from the Bristol-Myers Squibb collaboration due to an extended performance obligation term.
- Improved Net Loss: Net loss improved by 36.4% ($15.8 million) year-over-year. This improvement was driven by a significant reduction in Research and Development (R&D) expenses (down 29.4%) and a lower restructuring charge ($4.8 million vs. $16.1 million in 2010).
- Liquidity Surge: Cash and cash equivalents increased by $104.6 million, primarily due to a public offering of 17.3 million shares of common stock in March 2011, which generated net proceeds of approximately $179.3 million.
- Restructuring: The company implemented a restructuring plan in March 2011, reducing headcount by 24 employees. Combined with 2010 plans, the total workforce reduction reached 410 employees.
Outlook, Guidance, and Risks
- Cabozantinib Development: The company expects to release top-line results from the Phase 3 registration trial for medullary thyroid cancer in mid-2011 and potentially submit a New Drug Application (NDA) by the end of 2011. The FDA has granted Fast Track designation for this indication.
- Future Restructuring Costs: Management expects to incur additional restructuring charges of approximately $24.6 million to $29.6 million in 2011, primarily related to facility exits and sublease costs in South San Francisco.
- Debt Obligations:
- GlaxoSmithKline (GSK): A final installment of $36.2 million (principal and interest) is due on October 27, 2011. Repayment can be made in cash or stock.
- Deerfield: Secured convertible notes totaling $124.0 million principal. Mandatory prepayments begin in 2013 based on collaboration revenue.
- Silicon Valley Bank: An $80.0 million term loan due in 2017 requires the company to maintain a compensating balance of 100% of the principal ($80 million) in a non-interest-bearing account.
- Liquidity Outlook: The company anticipates that current cash, investments, and collaboration funding will sustain operations for at least 12 months. However, future capital requirements are substantial, and the company may need to raise additional funds.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $391.7 million in total liquid assets against the upcoming $36.2 million GSK payment due in October 2011 and the $80 million restricted cash requirement for the Silicon Valley Bank loan.
- Restructuring Execution: Monitor the actual costs incurred for facility exits and sublease negotiations, as the company estimates an additional $24.6 million to $29.6 million in charges for 2011.
- Clinical Milestones: Track the mid-2011 release of Phase 3 data for medullatory thyroid cancer, which is critical for the company's primary commercialization strategy.
- Revenue Recognition: Review the impact of the extended performance obligation term with Bristol-Myers Squibb on future license revenue recognition rates.
- Debt Conversion: Assess the potential dilution impact if the company elects to repay the GSK loan or Deerfield notes using common stock rather than cash.